- Home
- POAI vs CERO Comparison
POAI vs CERO Comparison
Compare POAI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAI
- CERO
- Stock Information
- Founded
- POAI 2002
- CERO 2017
- Country
- POAI United States
- CERO United States
- Employees
- POAI N/A
- CERO N/A
- Industry
- POAI Industrial Specialties
- CERO
- Sector
- POAI Health Care
- CERO
- Exchange
- POAI Nasdaq
- CERO Nasdaq
- Market Cap
- POAI 9.7M
- CERO 8.4M
- IPO Year
- POAI N/A
- CERO N/A
- Fundamental
- Price
- POAI $1.45
- CERO $1.79
- Analyst Decision
- POAI Hold
- CERO
- Analyst Count
- POAI 1
- CERO 0
- Target Price
- POAI N/A
- CERO N/A
- AVG Volume (30 Days)
- POAI 483.7K
- CERO 745.6K
- Earning Date
- POAI 03-27-2025
- CERO 03-04-2025
- Dividend Yield
- POAI N/A
- CERO N/A
- EPS Growth
- POAI N/A
- CERO N/A
- EPS
- POAI N/A
- CERO N/A
- Revenue
- POAI $1,484,223.00
- CERO N/A
- Revenue This Year
- POAI N/A
- CERO N/A
- Revenue Next Year
- POAI $569.48
- CERO N/A
- P/E Ratio
- POAI N/A
- CERO N/A
- Revenue Growth
- POAI N/A
- CERO N/A
- 52 Week Low
- POAI $0.55
- CERO $1.57
- 52 Week High
- POAI $3.67
- CERO $1,095.00
- Technical
- Relative Strength Index (RSI)
- POAI 50.83
- CERO 36.41
- Support Level
- POAI $1.39
- CERO $1.70
- Resistance Level
- POAI $1.97
- CERO $2.10
- Average True Range (ATR)
- POAI 0.14
- CERO 0.23
- MACD
- POAI -0.02
- CERO 0.23
- Stochastic Oscillator
- POAI 14.88
- CERO 33.85
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.